ADA Takes to the Streets in New Orleans
Enthusiasm for the host of clinical data released at the ongoing American Diabetes Association (ADA, June 5-9) meeting has simmered down as the FDA’s long-term safety concerns will weigh heavily on whether these drugs will actually make it to market. New data on weekly versions of GLP-1’s, Phase II data from Roche’s aleglitazar, and data for a novel class of drugs that aim to treat diabetes by blocking IL-1β were all important developments in the fight against diabetes, but they are unlikely…